CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 71 enrolled
Drug / intervention
Basiliximab 20 MGdrug
Likely dose
Basiliximab 20 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04104438
NCT04104438Phase 4Completed
CompareCT.gov

A Study in Adults on Pre LT Dialysis With Basiliximab, Delayed Tacrolimus (TAC), Mycophenolate (MMF), Steroids (Grp 1) vs. Basiliximab, Delayed TAC, MMF, Steroids, With Everolimus 30d Post LT(Grp 2), vs. TAC, MMF, Steroids (Grp 3).

Fady M Kaldas, M.D., F.A.C.S.·interventional·Posted Sep 26, 2019·Updated Dec 16, 2025

In Brief

A Phase 4 clinical trial evaluating Basiliximab 20 MG for Asses Immunosuppression Modulation on Renal Recovery Post LT. Completed, enrolled 71 participants across 1 site.

Detailed Summary

This is a study to help understand how well new combinations of immunosuppressive medications (medications that weaken your immune system to prevent your body from rejecting the transplanted liver) work compared to standard immunosuppressive medications after your liver transplant. Also the study will assess how safe the new combination of immunosuppressive medicines are and if there are any changes in how your kidneys work after taking these medicines.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsses Immunosuppression Modulation on Renal Recovery Post LT
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedSep 26, 2019
Enrollment StartJan 15, 2021
Primary CompletionSep 30, 2024
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 6.8 years ago

Interventions

Basiliximab 20 MGdrug

Basiliximab induction followed by tacrolimus, corticosteroids and mycophenolic acid with a switch to everolimus by post operative day 30